This study aimed
to deliver a cationic nanoemulsion carrying miconazole
nitrate (MCN) to control fungal infections using excipients for synergism.
Peceol (oil) and labrasol (surfactant) were selected based on maximum
solubility and zone of inhibition values against
Candida albicans
and
Aspergillus niger
. Optimized MCNE11 was evaluated
[size, zeta potential, % entrapment efficiency (%EE), % transmittance,
viscosity, refractive index, extrudability, polydispersity (PDI),
morphology, and pH]. An
in vitro
drug release study
was conducted for comparison between DS (drug suspension) and MNE11.
In vitro
hemolysis was studied at two different concentrations
(0.625 and 2.5 μg/mL). Permeation profiles were generated using
rat skin. A Draize test was conducted using rabbit to negate irritability
issues. Finally, a stability test of MCNE11 was conducted for 12 months.
The results showed that MCNE11 (cationic) was the most optimized in
term of size, %EE, and PDI. The drug release from MCNE11 was higher
compared to DS but comparable to MNE11 (anionic), suggesting no impact
of the imposed cationic charge on the release behavior. Moreover,
permeation parameters of MCNE11 were significantly (
p
< 0.05) greater than MNE11, which may be attributed to the combined
impact of size (low), surfactant (for reversible changes), and electrostatic
interaction (nanoglobules–skin surface). Thus, stable MCN11
possessing high %EE (89.8%), low size (145 nm), maximum flux (5.7
± 0.1 μg/cm
2
/h), high drug deposition (932.7
± 41.6 μg/cm
2
), optimal viscosity (44.17 ±
0.8 cP), low PDI (0.21), optimal zeta potential (+28.1 mV), and low
hemolysis can be promising alternatives to conventional cream to control
resistant and recurring types of fungal infections.